Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 16 | 2024 | 295 | 4.070 |
Why?
|
| Renal Replacement Therapy | 6 | 2023 | 29 | 2.080 |
Why?
|
| Nephrology | 3 | 2021 | 11 | 1.400 |
Why?
|
| Renal Dialysis | 5 | 2023 | 171 | 1.350 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2024 | 9 | 0.940 |
Why?
|
| Complement C3 | 1 | 2024 | 20 | 0.940 |
Why?
|
| Critical Care | 2 | 2018 | 215 | 0.910 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 55 | 0.850 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2024 | 304 | 0.770 |
Why?
|
| Hepatorenal Syndrome | 5 | 2023 | 11 | 0.750 |
Why?
|
| Anticoagulants | 3 | 2020 | 254 | 0.680 |
Why?
|
| Kidney Failure, Chronic | 3 | 2017 | 200 | 0.660 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 114 | 0.620 |
Why?
|
| Kidney | 2 | 2020 | 686 | 0.600 |
Why?
|
| Hemofiltration | 1 | 2017 | 7 | 0.580 |
Why?
|
| Postoperative Complications | 1 | 2024 | 1035 | 0.570 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 70 | 0.560 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 293 | 0.550 |
Why?
|
| Heparin | 1 | 2016 | 91 | 0.500 |
Why?
|
| Critical Illness | 1 | 2017 | 300 | 0.470 |
Why?
|
| Colloids | 1 | 2013 | 4 | 0.450 |
Why?
|
| Isotonic Solutions | 1 | 2013 | 18 | 0.450 |
Why?
|
| Albumins | 1 | 2013 | 31 | 0.450 |
Why?
|
| Fluid Therapy | 1 | 2013 | 75 | 0.430 |
Why?
|
| Mycobacterium Infections | 1 | 2011 | 10 | 0.390 |
Why?
|
| Mycobacterium | 1 | 2011 | 28 | 0.390 |
Why?
|
| Peritonitis | 1 | 2011 | 27 | 0.390 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 32 | 0.380 |
Why?
|
| Sepsis | 1 | 2013 | 227 | 0.360 |
Why?
|
| Vasoconstrictor Agents | 3 | 2023 | 83 | 0.360 |
Why?
|
| Humans | 24 | 2024 | 50389 | 0.340 |
Why?
|
| Angiotensinogen | 3 | 2013 | 12 | 0.320 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 2949 | 0.310 |
Why?
|
| Prognosis | 6 | 2024 | 1979 | 0.290 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 229 | 0.260 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2024 | 237 | 0.210 |
Why?
|
| Creatinine | 3 | 2018 | 144 | 0.210 |
Why?
|
| Male | 11 | 2024 | 25718 | 0.200 |
Why?
|
| Intensive Care Units | 2 | 2014 | 224 | 0.200 |
Why?
|
| Aged | 7 | 2024 | 9590 | 0.190 |
Why?
|
| Female | 12 | 2024 | 26981 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2018 | 745 | 0.170 |
Why?
|
| Middle Aged | 8 | 2024 | 12460 | 0.160 |
Why?
|
| Ultrasonography | 1 | 2021 | 438 | 0.160 |
Why?
|
| Uremia | 1 | 2018 | 12 | 0.150 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 15 | 0.150 |
Why?
|
| Rats | 1 | 2024 | 3287 | 0.150 |
Why?
|
| Vancomycin | 1 | 2018 | 79 | 0.140 |
Why?
|
| Citrates | 1 | 2016 | 10 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2017 | 85 | 0.130 |
Why?
|
| Echocardiography | 1 | 2019 | 398 | 0.130 |
Why?
|
| Research Design | 1 | 2018 | 344 | 0.130 |
Why?
|
| Proteomics | 1 | 2018 | 299 | 0.130 |
Why?
|
| Arterial Pressure | 1 | 2015 | 45 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 556 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2021 | 5230 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2018 | 397 | 0.120 |
Why?
|
| Empyema, Pleural | 1 | 2014 | 12 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2016 | 197 | 0.120 |
Why?
|
| Mice | 1 | 2024 | 5688 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 460 | 0.110 |
Why?
|
| Renin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Hypertension | 2 | 2019 | 550 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 213 | 0.110 |
Why?
|
| Pneumonia | 1 | 2014 | 118 | 0.110 |
Why?
|
| Resuscitation | 1 | 2013 | 73 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2013 | 59 | 0.110 |
Why?
|
| Adult | 5 | 2020 | 13568 | 0.100 |
Why?
|
| Patient Selection | 1 | 2013 | 257 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 201 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 174 | 0.090 |
Why?
|
| Time Factors | 1 | 2017 | 2934 | 0.090 |
Why?
|
| Animals | 1 | 2024 | 13173 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2013 | 1258 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 934 | 0.080 |
Why?
|
| Kidney Function Tests | 2 | 2019 | 49 | 0.070 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 48 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1042 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 2414 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2017 | 413 | 0.050 |
Why?
|
| Disease Progression | 2 | 2017 | 823 | 0.050 |
Why?
|
| Lypressin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 8 | 0.050 |
Why?
|
| Catheterization | 1 | 2021 | 101 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 963 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 24 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 671 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 66 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 79 | 0.040 |
Why?
|
| Colorimetry | 1 | 2018 | 11 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2019 | 266 | 0.040 |
Why?
|
| Cadaver | 1 | 2018 | 96 | 0.040 |
Why?
|
| Manikins | 1 | 2018 | 35 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1201 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 3692 | 0.030 |
Why?
|
| United States | 2 | 2021 | 4913 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 704 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 137 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2018 | 130 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 284 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 118 | 0.030 |
Why?
|
| Octreotide | 1 | 2015 | 9 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 592 | 0.030 |
Why?
|
| Midodrine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Norepinephrine | 1 | 2015 | 113 | 0.030 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2014 | 9 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2014 | 11 | 0.030 |
Why?
|
| Thoracoscopy | 1 | 2014 | 17 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1017 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1426 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 60 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 490 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2013 | 179 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 280 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 239 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2015 | 6223 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 455 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 583 | 0.020 |
Why?
|
| Heart Failure | 1 | 2017 | 526 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 316 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 449 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 900 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2219 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 3180 | 0.020 |
Why?
|